INT91401

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 2000
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 12
Total Number 13
Disease Relevance 4.10
Pain Relevance 4.47

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (OGFR) cellular_component (OGFR) cytoplasm (OGFR)
Anatomy Link Frequency
thyroid 3
neck 2
colon 2
head 2
OGFR (Homo sapiens)
Pain Link Frequency Relevance Heat
Opioid 128 100.00 Very High Very High Very High
Enkephalin 14 99.88 Very High Very High Very High
narcan 10 99.76 Very High Very High Very High
antagonist 30 99.44 Very High Very High Very High
methadone 270 99.10 Very High Very High Very High
agonist 44 98.52 Very High Very High Very High
Endogenous opioid 16 86.20 High High
Morphine 36 58.00 Quite High
Buprenorphine 176 50.00 Quite Low
opioid receptor 74 44.96 Quite Low
Disease Link Frequency Relevance Heat
Cancer 30 97.24 Very High Very High Very High
Skin Cancer 6 97.24 Very High Very High Very High
Colon Cancer 20 96.84 Very High Very High Very High
Disease 3 93.64 High High
Wound Healing 2 92.88 High High
Retinoblastoma 2 86.04 High High
Head & Neck Cancer 2 75.00 Quite High
Death 8 72.36 Quite High
Opiate Addiction 54 62.48 Quite High
Thyroid Neoplasm 12 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Blockade of OGF-OGFr interactions with naloxone abolished the increased expression of p16 protein by OGF.
OGF-OGFr Binding (interactions) of associated with narcan
1) Confidence 0.41 Published 2007 Journal Cancer Res. Section Abstract Doc Link 17974995 Disease Relevance 0.22 Pain Relevance 0.25
Specific and saturable binding of OGFr was found in all thyroid samples.
OGFr Binding (binding) of in thyroid
2) Confidence 0.36 Published 2008 Journal Thyroid Section Body Doc Link 19014324 Disease Relevance 0.08 Pain Relevance 0
Blockade of OGF-OGFr interactions with naloxone abolished the increased expression of p16 protein by OGF.
OGF-OGFr Binding (interactions) of associated with narcan
3) Confidence 0.31 Published 2007 Journal Cancer Res. Section Abstract Doc Link 17974995 Disease Relevance 0.22 Pain Relevance 0.25
METHODS: Patient samples of thyroid cancers and goiter were collected at the time of resection and processed for immunohistochemistry of OGF and OGFr, as well as pharmacological binding assays for OGFr.
OGFr Binding (binding) of in thyroid
4) Confidence 0.31 Published 2008 Journal Thyroid Section Body Doc Link 19014324 Disease Relevance 0.09 Pain Relevance 0
METHODS: Patient samples of thyroid cancers and goiter were collected at the time of resection and processed for immunohistochemistry of OGF and OGFr, as well as pharmacological binding assays for OGFr.
OGFr Binding (binding) of in thyroid
5) Confidence 0.31 Published 2008 Journal Thyroid Section Body Doc Link 19014324 Disease Relevance 0.09 Pain Relevance 0
In a previous study, OGFr binding activity was found to decrease in concert with progression of human squamous cell carcinoma of the head and neck (SCCHN).
OGFr Binding (binding) of in neck associated with skin cancer
6) Confidence 0.31 Published 2006 Journal Int. J. Oncol. Section Abstract Doc Link 16820893 Disease Relevance 0.43 Pain Relevance 0.33
OGFr binding affinity and capacity, as well as transcriptional activity of OGFr, were not influenced by the size or state of differentiation of pancreatic or colon tumors.
OGFr Binding (affinity) of in colon associated with colon cancer
7) Confidence 0.31 Published 2006 Journal Int. J. Oncol. Section Abstract Doc Link 16820893 Disease Relevance 0.78 Pain Relevance 0.27
OGFr binding affinity and capacity, as well as transcriptional activity of OGFr, were not influenced by the size or state of differentiation of pancreatic or colon tumors.
OGFr Binding (affinity) of in colon associated with colon cancer
8) Confidence 0.31 Published 2006 Journal Int. J. Oncol. Section Abstract Doc Link 16820893 Disease Relevance 0.85 Pain Relevance 0.27
To investigate the target of OGF as to cell proliferation, the effects of excess OGF, and a deprivation of OGF-OGFr interaction by an opioid antagonist, naltrexone (NTX), were examined in 3 human cancer cell lines: pancreatic (BxPC-3), colon (HT-29), and head and neck (CAL-27).
OGF-OGFr Binding (interaction) of in head associated with cancer, antagonist and opioid
9) Confidence 0.31 Published 2000 Journal Int. J. Oncol. Section Abstract Doc Link 11029512 Disease Relevance 0.28 Pain Relevance 0.39
On the other hand, fetal exposure to an opioid antagonist, (e.g. naltrexone) may prevent [Met5]-enkephalin from binding to the opioid growth factor receptor, thereby blocking the growth-inhibitory effects of the OGF-OGFr complex [405, 435, 440, 441]; in other words, the brake is removed and growth is accelerated.
opioid growth factor Binding (binding) of associated with antagonist, enkephalin and opioid
10) Confidence 0.25 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2647150 Disease Relevance 0.19 Pain Relevance 0.95
Developmental delays observed after fetal exposure to agonists, such as heroin or methadone, are postulated to result from their direct interaction with OGFr, retarding “normal” fetal development.
OGFr Binding (interaction) of associated with agonist and methadone
11) Confidence 0.22 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2647150 Disease Relevance 0.14 Pain Relevance 1.01
In a previous study, OGFr binding activity was found to decrease in concert with progression of human squamous cell carcinoma of the head and neck (SCCHN).
OGFr Binding (binding) of in head associated with skin cancer
12) Confidence 0.11 Published 2006 Journal Int. J. Oncol. Section Abstract Doc Link 16820893 Disease Relevance 0.43 Pain Relevance 0.33
To investigate the target of OGF as to cell proliferation, the effects of excess OGF, and a deprivation of OGF-OGFr interaction by an opioid antagonist, naltrexone (NTX), were examined in 3 human cancer cell lines: pancreatic (BxPC-3), colon (HT-29), and head and neck (CAL-27).
OGF-OGFr Binding (interaction) of in neck associated with cancer, antagonist and opioid
13) Confidence 0.11 Published 2000 Journal Int. J. Oncol. Section Abstract Doc Link 11029512 Disease Relevance 0.28 Pain Relevance 0.39

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox